Theoretical Modelling of Potential Chk1 Inhibitors

被引:0
|
作者
Araujo, Pedro M. M. [1 ]
da Silva, Luis Pinto [1 ]
Esteves da Silva, Joaquim C. G. [1 ]
机构
[1] Univ Porto, Fac Ciencias, Dept Quim & Bioquim, Ctr Invest Quim, P-4169007 Oporto, Portugal
关键词
Checkpoint kinase 1; Chk1; inhibition; enzyme-inhibitor interactions; molecular design; semi-empirical calculations; p53-deficient tumor; FREE-ENERGY CALCULATION; PROTEIN-KINASES; BINDING; CANCER; SENSITIZATION; OPTIMIZATION; MECHANISM;
D O I
暂无
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In this contribution, we attempted to design novel inhibitors of the serine/threonine-protein kinase Chk1. After studying the interaction of Chk1 ATP binding site with known inhibitor C39, we created seven modified C39-based molecules in order to achieve higher binding potentials. Of those, modified molecules 2, 4, 6 and 7 (MD2, MD4, MD6 and MD7) were selected to be assembled in three new molecules, originating MD8, MD9 and MD10. When compared to C39, MD8 and MD9 showed significant improvements in the binding energy while MD10 had a smaller gain. MD9 achieved the best improvement (21%) and MD8 the second best (19%) while MD10 only reached a 6% improvement.
引用
收藏
页码:60 / 65
页数:6
相关论文
共 50 条
  • [1] ATR/CHK1 inhibitors and cancer therapy
    Qiu, Zhaojun
    Oleinick, Nancy L.
    Zhang, Junran
    RADIOTHERAPY AND ONCOLOGY, 2018, 126 (03) : 450 - 464
  • [2] Granulatimide analogues as potent Chk1 inhibitors
    Prudhomme, Michelle
    Henon, Helene
    Hugon, Bernadette
    Anizon, Fabrice
    Pfeiffer, Bruno
    Leonce, Stephane
    Pierre, Alain
    Golsteyn, Roy
    Hickman, John
    CANCER RESEARCH, 2006, 66 (08)
  • [3] Development of thioquinazolinones, allosteric Chk1 kinase inhibitors
    Converso, Antonella
    Hartingh, Timothy
    Garbaccio, Robert M.
    Tasber, Edward
    Rickert, Keith
    Fraley, Mark E.
    Yan, Youwei
    Kreatsoulas, Constantine
    Stirdivant, Steve
    Drakas, Bob
    Walsh, Eileen S.
    Hamilton, Kelly
    Buser, Carolyn A.
    Mao, Xianzhi
    Abrams, Marc T.
    Beck, Stephen C.
    Tao, Weikang
    Lobell, Rob
    Sepp-Lorenzino, Laura
    Zugay-Murphy, Joan
    Sardana, Vinod
    Munshi, Sanjeev K.
    Jezequel-Sur, Sylvie Marie
    Zuck, Paul D.
    Hartman, George D.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (04) : 1240 - 1244
  • [4] Optimization of a pyrazoloquinolinone class of Chk1 kinase inhibitors
    Brnardic, Edward J.
    Garbaccio, Robert M.
    Fraley, Mark E.
    Tasber, Edward S.
    Steen, Justin T.
    Arrington, Kenneth L.
    Dudkin, Vadim Y.
    Hartman, George D.
    Stirdivant, Steven M.
    Drakas, Bob A.
    Rickert, Keith
    Walsh, Eileen S.
    Hamilton, Kelly
    Buser, Carolyn A.
    Hardwick, James
    Tao, Weikang
    Beek, Stephen C.
    Mao, Xianzhi
    Lobell, Robert B.
    Sepp-Lorenzino, Laura
    Yan, Youwei
    Ikuta, Mari
    Munshi, Sanjeev K.
    Kuo, Lawrence C.
    Kreatsoulas, Constantine
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (21) : 5989 - 5994
  • [5] MYC amplification sensitizes TNBC to CHK1 inhibitors
    Li, Bin
    Liu, Tiantian
    Zhao, Mingchuan
    Guo, Duancheng
    Peng, Wenxia
    Tao, Zhonghua
    Hu, Xichun
    Jin, Juan
    CELLULAR SIGNALLING, 2025, 131
  • [6] Synthesis of selenophene derivatives as novel CHK1 inhibitors
    Hong, Pao-Chiung
    Chen, Li-Jung
    Lai, Tzu-Yun
    Yang, Huei-Yu
    Chiang, Shih-Jan
    Lu, Yann-Yu
    Tsai, Ping-Kuei
    Hsu, Hung-Yi
    Wei, Win-Yin
    Liao, Chu-Bin
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (17) : 5065 - 5068
  • [7] Synthesis and development of potent Chk1 kinase inhibitors
    Huang, Shaei
    Garbaccio, Rob
    Tasber, Edward S.
    Fraley, Mark E.
    Steen, Justin T.
    Yan, Youwei
    Munshi, Sanjieev
    Ikuta, Mari
    Kuo, Lawrence
    Kreatsoulas, Constantine
    Reilly, Michael
    Mahan, Elizabeth
    Stirdivant, Steve
    Drakas, Bob
    Rickert, Keith
    Walsh, Eileen
    Hamilton, Kelly
    Buser, Carolyn A.
    Hardwick, James
    Mao, Xianzhi
    Beck, Steve
    Abrams, Marc
    Tao, Weikang
    Lobell, Rob
    Sepp-Lorenzino, Laura
    Hartman, George D.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 238
  • [8] Exploring the effects of PARP inhibition on CHK1 activation as a potential determinant of synergy with CHK1 inhibition.
    Wielgos-Bonvallet, Monicka
    Cybulska, Paulina
    Van Oudenhove, Elke
    Jelinic, Petar
    Levine, Douglas A.
    CLINICAL CANCER RESEARCH, 2018, 24 (15) : 28 - +
  • [9] Assessment of Chk1 Phosphorylation as a Pharmacodynamic Biomarker of Chk1 Inhibition
    Parsels, Leslie A.
    Qian, Yushen
    Tanska, Daria M.
    Gross, Marisa
    Zhao, Lili
    Hassan, Maria C.
    Arumugarajah, Sankari
    Parsels, Joshua D.
    Hylander-Gans, Linda
    Simeone, Diane M.
    Morosini, Deborah
    Brown, Jeffrey L.
    Zabludoff, Sonya D.
    Maybaum, Jonathan
    Lawrence, Theodore S.
    Morgan, Meredith A.
    CLINICAL CANCER RESEARCH, 2011, 17 (11) : 3706 - 3715
  • [10] BRD7 suppresses tumor chemosensitivity to CHK1 inhibitors by inhibiting USP1-mediated deubiquitination of CHK1
    Li, Lemin
    Wang, Linchen
    Liu, Dian
    Zhao, Yongchao
    CELL DEATH DISCOVERY, 2023, 9 (01)